title: Cytoskeletal-antigen specific immunoliposome-targeted in vivo preservation of myocardial viability.
abstract: Preservation of cell viability using Cytoskeletal-antigen Specific ImmunoLiposomes (antimyosin-CSIL) has been demonstrated in cell cultures. The current study utilized the same CSIL intervention for myocardial protection in an in vivo rabbit model of acute myocardial infarction. Rabbit hearts with experimental left ventricular myocardial infarction were treated with CSIL; control liposomes, [(CL), IgG-liposomes (IgG-L) or plain liposomes (PL)], or vehicle (placebo). Mean myocardial infarct size in rabbit hearts treated in vivo with CSIL was 5 times smaller than in those treated with non-specific CL or vehicle. Treatment of ischemic adult myocardium with CSIL results in significant preservation of myocardial viability by dramatically decreasing the infarct size relative to CL or placebo treatment. Immunohistochemical myocardial preservation of CSIL-treated hearts was confirmed by the lack of contraction band necrosis using histological H&E stains relative to controls. Electrocardiographic confirmation of reduction in myocardial injury after CSIL therapy relative to controls was also observed. Application of CSIL technology to non-cardiac tissues would confirm a broader applicability of this cell membrane lesion sealing technology.
authors.affiliation: Center for Cardiovascular Targeting, Northeastern University, Bouve College of Health Sciences, School of Pharmacy, Boston, MA 02115, United States. b.khaw@neu.edu <b.khaw@neu.edu>
authors.forename: Ban-An
authors.initials: BA
authors.lastname: Khaw
authors.forename: Jose
authors.initials: J
authors.lastname: DaSilva
authors.forename: William C
authors.initials: WC
authors.lastname: Hartner
mesh_terms: D000818:Animals; D002470:Cell Survival; D002626:Chemistry, Pharmaceutical; D002784:Cholesterol / Q000737:chemistry; D003599:Cytoskeleton / Q000276:immunology*; D004195:Disease Models, Animal; D004339:Drug Compounding; D004562:Electrocardiography; D006352:Heart Ventricles / Q000473:pathology; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D007150:Immunohistochemistry; D008055:Lipids / Q000737:chemistry*; D008081:Liposomes; D009203:Myocardial Infarction / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D009218:Myosins / Q000276:immunology*; D009336:Necrosis; D010713:Phosphatidylcholines / Q000737:chemistry; D011817:Rabbits
chemical_list: D007074:Immunoglobulin G; D008055:Lipids; D008081:Liposomes; D010713:Phosphatidylcholines; D002784:Cholesterol; D009218:Myosins